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Endothelial cellBlood vessel formation depends on the highly coordinated actions of a variety of angiogenic regulators.
Vascular endothelial growth factor (VEGF) and Angiopoietin-1 (Ang-1) are both potent and essential
proangiogenic factors with complementary roles in vascular development and function. Whereas VEGF is
required for the formation of the initial vascular plexus, Ang-1 contributes to the stabilization and maturation
of growing blood vessels.
Here, we provide evidence of a novel microRNA (miRNA)-dependent molecular mechanism of Ang-1 signalling
modulation aimed at stabilizing adult vasculature. MiRNAs are short non-coding RNA molecules that
post-trascriptionally regulate gene expression by translational suppression or in some instances by cleavage of
the respective mRNA target. Our data indicate that endothelial cells of mature vessels express high levels of
miR-126, which primarily targets phosphoinositide-3-kinase regulatory subunit 2 (p85β). Down-regulation of
miR-126 and over-expression of p85β in endothelial cells inhibit the biological functions of Ang-1. Additionally,
knockdown of miR-126 in zebraﬁsh resulted in vascular remodelling and maturation defects, reminiscent of the
Ang-1 loss-of-function phenotype. Our ﬁndings suggest that miR-126-mediated phosphoinositide-3-kinase
regulation, not only ﬁne-tunes VEGF-signaling, but it strongly enhances the activities of Ang-1 on vessel stabili-
zation and maturation.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Vascular development is a complex, tightly regulated, multi-step
process. A number of secreted factors regulate endothelial cells (EC)
migration, proliferation and differentiation into vascular structures.
Vascular endothelial growth factor-A (VEGF) and Angiopoietin 1
(Ang-1) play essential and complementary roles in vessel formation
during embryogenesis. Both VEGF and Ang-1 share the ability to pro-
mote endothelial survival, proliferation, and migration, by acting on
their cognate cell-surface tyrosine-kinase receptors, VEGFR2 (Flk1,
KDR) and Tie-2 (Tek), respectively. Whereas VEGF is required for the
formation of the initial vascular plexus in early phases of development,
Ang-1 is necessary for subsequent vascular remodeling into matureendothelial growth factor-A;
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rights reserved.blood vessels [1,2]. However, it appears that while both Ang-1 and
VEGF initiate angiogenesis, only Ang-1 leads to maturation of the
vessels. In addition, VEGF can cause vascular instability by promoting
permeability and tissue edema, whereas Ang-1 stabilizes existing
vessels causing decreased vascular leakage [3,4]. Despite their opposing
actions onpermeability, Ang-1 andVEGF act in a coordinatedwayduring
embryonic vascular development [5]. There is therefore a competitive
balance that must be weighed up between VEGF and Ang-1. Initial
capillary budding is induced by both VEGF and Ang-1 followed by stabi-
lization of the neovessel for maturation by Ang-1 alone [4]. When all
vessels are completely stable, no new vessels could be formed as
budding would not occur. Findley et al. [6] demonstrated that VEGF
induces Tie-2 shedding and once cleaved, sTie-2 binds to both Ang-1
and Ang-2 to inhibit ligand-mediated Tie-2 receptor activation and
downstream signaling [6]. This suggests a mechanism by which VEGF
down-regulates thematuration and remodeling effects of Ang-1 causing
resultant neovascularization.
Recently it has been demonstrated that a new class of regulatory
molecules -microRNA (miRNA) - is actively involved in the processes
of vascular development and angiogenesis [7–9]. MiRNA generally
repress targetmRNAs through an antisensemechanism [10]. In animals,
1926 R. Sessa et al. / Biochimica et Biophysica Acta 1823 (2012) 1925–1935miRNAs typically target sequences in the transcript 3′ untranslated re-
gions (3′UTRs) that are only partially complementary to the miRNA,
causing translational suppression, or in some instances, cleavage of
the respective mRNA target [11]. Speciﬁc endothelial miRNAs have
been implicated in controlling cellular responses to angiogenic stimuli,
and particularly to VEGF, suggesting that miRNAs may be key modula-
tors of angiogenic signal transduction pathways [12–15].
Here we show that mature vessels express high levels of miR-126,
which enhances the remodeling and stabilization effect of Ang-1.
MiR-126 potentiates phosphoinositide-3-kinase (PI3K)-mediated
Ang-1 signaling by reducing levels of the PI3K regulatory subunit 2
(p85β).
2. Materials and methods
2.1. Cell cultures and growth factors
Human umbilical vein EC (HUVEC) were isolated as previously
described [16]. EC were seeded onto gelatin-coated culture dishes and
cultured in EGM-2™ medium (EGM-2 BulletKit™ medium (CC-3162,
Lonza). 293T (ATCC CRL-1573), Hela (ATCC CCL-2) and H-end [17] cell
lines were grown in DME (Cambrex) supplemented with 10% FCS,
2 mM L-glutamine (Cambrex) and antibiotics. Recombinant VEGF-
A165 and Ang-1 were purchased from R&D Systems.
2.2. Constructs, cDNA, oligos and transfection
The plasmid used for the identiﬁcation of the target of miR-126 by
microarray experiments wasmade starting from pEGFP-N1 (Clontech).
The sequence bearing three miR-126 consensus response elements
(GCATTATTACTCACGGTACGA) was cloned downstream of the EGFP
coding sequence into XbaI-NotI sites. The sequence introduced into
the plasmid was:gaatctagaaGCATTATTACTCACGGTACGAgatactGCATTA
TTACTCACGGTACGAactagtGCATTATTACTCACGGTACGAta; with the miR-
126 complementary sequence shown in upper case.
Human p85β coding sequence was cloned in the third-generation
lentivirus vector #304.pCCL.sin.cPPT.polyA.CTE.eGFP.minhCMV.hPGK.
deltaNGFR.Wpre and inserted into SalI-PstI sites. MOI of two was
employed for the over-expression study on HUVEC.
Loss-of-function assay was performed on EC transiently transfected
with hsa-miR-126 oligo (named anti-miR-126): cgcattattactcacggtacga,
and negative control hsa-miR-Scrambled (named anti-miR-Scr) oligo:
gcgtaacacgtctatacgccca, purchased from Exiqon. Cells were transfected
with Lipofectamine Plus (Invitrogen) or Oligofectamine (Invitrogen)
according to the manufacturer's instructions.
Western blots concerning the loss-of-function experiments were
carried out using the commercially available lentivirus vectors
miRZip™ (SystemBio). HUVEC were infected with MOI of 2,5 and
propagated for one week, the quantiﬁcation of the phospho Akt1
level was performed considering a triplicate of experiments.
2.3. Luciferase assay
p85β 3′UTR sequence was cloned into the pIS1 plasmid between
SacI sites (Derived from pRL-TK AddGene) down-stream from the
Renilla coding sequence. The cloning procedure was performed by
recombination using the In-Fusion™ 2.0 Dry-Down PCR Cloning Kit
(Clontech Laboratories) with the following primers: Fw aacaataattctag
gagctcaactcccccaccccatatc and Re tcgagaccggtatagagctccgacgtttgatgt
tttatatcatatc. Mutated p85β 3′UTR was derived from wild-type p85β
3′UTR deleting the predicted miR-126 binding site with Phusion
Site-DirectedMutagenesis Kit (Finnzymes) using the following primers:
Fw [Phospho]cgaccatcaaacgtcggagc Re [Phospho] cactgcctcccagctcgtg.
Renilla luciferase activity was quantiﬁed in lysates using the Dual Lucif-
erase Report Assay kit (Promega) according to the manufacturer's rec-
ommendations. Luminescence readings were corrected for backgroundand Renilla luciferase values were normalized to total protein content
for each lysate.
2.4. Lentivirus production
Lentivirus vector stock was produced in 293T cells by calcium
phosphatase-mediated transfection of the vector of interest plus
packing plasmid (pCMV-R 8.74) and the envelope plasmid
(pMD2.VSVG) with the ProFection Mammalian Transfection System —
Calcium Phosphate (Promega) according to themanufacturer's instruc-
tions. Virus particles were collected 24 and 48 h post transfection,
ﬁltrated (0.22-μm pore), and used directly after concentration by ultra-
centrifugation (12,000 g for 2 h). Virus titers were assessed by trans-
ducing HeLa cells of EC with serial dilutions of viral stocks and the
multiplicity of infection (MOI) was determined (after 72 h) by FACS
analysis of the GFP+ cells. Aliquots of virus, plus 4 μg/ml of polybrene,
were used to infect exponentially growing cells.
For lentivirus‐driven p85β shRNA, three different short-hairpin
RNAs against human p85β: TCRN0000199567; TRCN0000039683;
TRCN0000199696 were named shRNA #1; #2; #3 respectively, and
were purchased fromMISSION ® TCR-Hs1.0 (Sigma). Self inactivating
lentiviral particles were produced as described above.
2.5. Quantitative RT-PCR (qRT-PCR)
Total RNA was harvested from different cell lines using TRIzol®
reagent (Invitrogen Life Technologies). qRT-PCRs for miR detection on
human and mouse endothelial cells were performed with the indicate
TaqMan MicroRNA Assays (Applied Biosystems) on 10 ng total RNA,
according to the manufacture's instructions. Analogous procedure has
been adopted for the analysis of the expression of 158 different
miRNA sequences. Analysis of miR-126 expression level in Zebraﬁsh
embryos was performed by using the NCode™ miRNA First-Strand
cDNA Synthesis Kit and qRT-PCR kit (Invitrogen). Four different
dre-microRNAs (miR-15a; miR-31, miR-108; miR-154) were tested by
qPCR analysis on different Zebraﬁsh developmental stages in order to
ﬁnd out which would be the most suitable for use as a reference gene
to normalize the expression level of themiR-126. The list of the possible
reference candidates was based on the Wienholds et al. data [18] in
which it was determined the temporal and spatial expression patterns
of 115 conserved vertebrate miRNAs in zebraﬁsh embryos by
microarrays and by in situ hybridization. Among the tested miRNAs
the dre-miR-15a was used as reference gene to normalize miRNA
expression level. The qPCR analysis was performed with the following
primers: dre-miR-126 (TCGTACCGTGAGTAATAATGC), dre-miR-15a
(TAGCAGCACAGAATGGTTTGTG). Quantitative normalization was
performed on the expression of the miR-16. p85β and KDR mRNAs
were retrotranscribed with the High Capacity cDNA Reverse Transcrip-
tion Kits (Applied Biosystems) and analyzed by quantitative real-time
reverse transcription-PCR (RT-PCR) using TaqMan Gene Expression
Assay fromApplied Biosystems.mRNA quantitieswere analyzed in trip-
licate, normalized against human GAPDH or human TBP as control
genes. qPCR reactions were performed on the ABI Prism 7900 HT
Sequence Detection System (Applied Biosystems) using ﬂuorescent
TaqMan methodology. Results are expressed as relative gene expres-
sion using the ΔΔCt method.
2.6. AnnexinV assay and nucleosome detection
Apoptosis was induced in EC by the serum deprivation method.
Brieﬂy, EC were seeded onto 1% gelatin-precoated six-well dishes to
a density of 1.75×105 cells per well. Cells were cultured in EGM-2
medium (Cambrex), washed extensively with EBM-2 serum-free
medium before incubation for 24–48 h in EBM-2 serum-free medium
or with VEGF 50 ng/ml and Ang-1 300 ng/ml. All ﬂoating and adherent
cells were collected after 1 min of trypsinization at 37 °C, washed with
1927R. Sessa et al. / Biochimica et Biophysica Acta 1823 (2012) 1925–1935PBS (Cambrex) then stained with Alexa 647 conjugated annexin V and
CytotoxBlue reagents (Invitrogen).The samples were then immediately
analyzed using ﬂow cytometry for viable (annexin V-negative and
cytotox-negative), early apoptotic (annexin V-positive, cytotox-
negative), or late apoptotic / secondary necrotic (annexin V-positive
and cytotox positive). Incubation was carried out at room temperature
for 15 min using the Alexa 647 conjugated annexin V and four 5 min
using Cytotox Blue.
Histone-associated DNAfragments were determined by Cell Death
Detection ELISAplus (Roche) in accordance with the manufacturer's
instruction. Brieﬂy, 4×104 HUVEC were cultured in 24 wells and
incubated in EBM-2 serum free medium or with VEGF 50 ng/ml and
Ang-1 200 ng/ml stimulation. Cell lysates from 1×104 were placed in
a streptavidin-coated micro-plate. A mixture of anti-histone-biotin
and anti-DNA-POD was added followed by incubation for 2 h at room
temperature. After removal of unbound antibodies by washing, POD
was determined photometrically at 405 nm with ABTS as a substrate.
2.7. Western blot analysis
For lysates, cells were serum deprived for 2.5 h and stimulated
with VEGF 50 ng/ml or Ang-1 300 ng/ml for varying times from
10–15 min. Total proteins were extracted in Laemmli buffer
(62.5 mM Tris–HCl, pH 6.8, 2% SDS and 10% glycerol) and quantiﬁed;
an equal amount of each sample was then resolved by SDS-PAGE and
transferred to PVDF membrane. After blocking with TBS/0.1% Tween
20/5% BSA, membranes were incubated with primary antibody over-
night at 4 °C. The following primary antibodies were used: rabbit
α-pS473Akt, mouse α-γTubulin, α-p85β (all from Cell Signaling
Technology). Lysates were subjected to immunoblotting, and visual-
ized by the enhanced chemiluminescence system.
2.8. Zebraﬁsh embryo microinjection and in situ hybridization
Wild Type and Tg(ﬂk:GFP)s843 embryos were injected at the one-cell
stage with 1 nl of 10 mM morpholino (MO) against the miR-126
sequence or standard control (Gene-Tools). Embryo development was
assessed at 24–72 h post-fertilization. For in situ hybridization the
probe matching with the miR-126 sequence, was Digoxigenin labelled
(Exiqon). Embryos were treated with proteinase K 10 μg/ml and ﬁxed
in 4% paraformaldehyde solution for 20 min at room temperature.
Hybridization was performed in 50% formaldehyde solution with SSC
5X buffer, 0.1% Tween, 1 M citric acid, pH 6.0, heparin 50 μg/ml, tRNA
500 μg/ml. As pre-incubation, embryos were ﬁrst soaked in the hybrid-
ization buffer for 2 h, after which they were incubated overnight in the
presence of Digoxigenin labelled probe (Exiqon) to aﬁnal concentration
of 40 nM (incubation temperature 53 °C). Washes were performed, ini-
tially with hybridization buffer and subsequently with SSC/PBS-0.1%
Tween, embryos were then incubated overnight with an antibody
against Digoxigenin. The antibody was alkaline phosphatase (AP) con-
jugated and the AP activity was detected by NBT/BCIP color reaction.
2.9. Mouse aortic ring angiogenesis assay
C57BL/6J mice were obtained from the Charles River Laboratories
Italia s.r.l. (Calco, Lecco, Italy) and were housed in the animal facility
of the Center for Comparative Oncology of the Fondazione Piemontese
per la Ricerca sul Cancro.
Thoracic aortas were removed from 8- to 12-week old wild-type
C57/BL6 mice (Charles River) and ﬁbroadipose tissue was dissected
away. Aortas were sectioned in 1-mm-long aortic rings and incubated
for 2 days in serum-free medium with antibiotics, polybrene and
lentiviral supernatant. Forty-eight-well dishes were coated with
100 μl of Basement Membrane Extract (BME) (Matrigel®, BD) and
allowed to solidify. Then aortic rings mixed with BME were loaded
into the coated wells together with growth factor (VEGF 50 ng/ml,Ang-1 300 ng/ml). Tubular structures were examined with an
inverted-phase contrast microscope (Leica Microsystems). Lengths
of sprout outgrowth were quantiﬁed with the imaging software
winRHIZO Pro (Reagent Instruments).
2.10. Endothelial spheroid assay
EC at concentration of 4000 cells/ml were re-suspended in 20%
methylcellulose (Sigma-Aldrich) and placed overnight in non-
adhesive multi-well plate. Then spheroids were collected and placed
in type-I collagen gel from rat tail (Roche) together with growth factors
(VEGF 50 ng/ml, Ang-1 300 ng/ml) for 24 h. Tubular structures
were examined with an inverted-phase contrast microscope (Leica
Microsystems). Lengths of sprout outgrowth were quantiﬁed with the
imaging software winRHIZO Pro (Reagent Instruments).
2.11. Microarray and bioinformatics analysis
For the analysis on Illumina Beadchips, biotin cRNA synthesis was
carried out through Illumina TotalPrep RNA Ampliﬁcation Kit
(Ambion) according to the manufacturer's protocol. Brieﬂy, 500 ng
of Total RNA were reverse-transcribed to single strand cDNA with
T7-oligodT primers. Subsequently, ss-cDNA was copied to ds-cDNA
and used for an in-vitro transcription to obtain biotin–cRNA. Qualitative
and quantitative assessment on cRNAs was obtained with the
Bioanalyzer 2100. Hybridization was carried out for 20 h at 55 °C
on Illumina “HumanRef-8_V2” beadchip, interrogating 24.000 RefSeq
sequences, using 850 ng of cRNA and standard protocols. The following
day, beadchips were washed, blocked and stained with Cy3-
streptavidin (Amersham). Finally the BeadArray Reader (Illumina)
was used to acquire ﬂuorescence images from the beadchips. Data
were processed with Rank Invariant Normalization, from the
BeadStudio software 1.5.13, and ﬁltering by Detection: if the detection
value for both samples in at least one replicate was higher than 0.99,
the probeswere kept for further analysis. Expression valueswere scaled
to remove negative values adding 60 expression values.
Expression data have been uploaded on the GEO database with the
accession number GSE32089.Microarray statistical analysis was initially
performed by ﬁltering probes affected by the oligonucleotides transfec-
tion. Geneswith absolute log2ratio between anti-miR-Scr and untreated
EC higher than 1were removed. Differentially expressed genes between
anti-miR-Scr and anti-miR-126 were deﬁned on the basis of a double
ﬁlter: genes having a pb0.05 and an absolute log2ratio above 0.7. Signif-
icance was estimated on the basis of hyper geometric distribution
p-values comparing the occurrence of miR targets in the signature
with respect to the universe, deﬁned as the genes expressed in
untransfected cells. In order to individuate predict seed sequences for
miR-126 in the 3′UTR of up-regulated genes, a bioinformatics analysis
was performed. MiR-126 targets enrichment was analyzed on the
basis of the Miranda database, as provided by Diana miRGen [19].
2.12. Ethical statements
Human umbilical vein endothelial cells (HUVEC) were obtained
fromhuman umbilical cords kindly donated byO.I.R.M- S. AnnaHospital
(Agreement n.619, 19/06/07) with prior written informed consent.
Animal housing and procedures involving mice were completed in
accordance with Italian Ministry of Health (D.L. 162/1979) and the
ethical guidelines for animal care of the European Community Council
(directive 86/609/ECC). Experiments performed were approved by
the local ethical committee (Ethical Committee for Animal experi-
mentation of the Fondazione Piemontese per la Ricerca sul Cancro).
For research on zebraﬁsh embryos, current Italian national rules do
not need approval. Zebraﬁsh were raised andmaintained according to
EU regulations on laboratory animals.
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The error bars on the charts represent the mean±S.E.M, unless
otherwise stated. Statistical signiﬁcance was determined by two-tailed
Student's t-test and p values less than 0.05 were considered to be
signiﬁcant.
3. Results
3.1. miR-126 is speciﬁcally expressed in the endothelium
In order to identify the miRNA expressed by the vascular endothe-
lium we analyzed miRNA expression levels in cells derived from
endothelial and other tissues. We identiﬁed the miR-126 as the
most speciﬁcally expressed miRNA in EC of different origin including
HUVEC, dermal microvascular EC and murine immortalized EC, while
it was almost absent in ﬁbroblasts, smooth muscle cells and epithelial
cells (Fig. 1a and Fig. S1). The miR126 expression level in EC was not
regulated by serum starvation or by VEGF-A stimulation (Fig. S2). To
conﬁrm the restricted endothelial expression of miR-126, in situ
hybridization analysis was performed on zebraﬁsh embryos using LNA
(Locked Nucleic Acid) probes. At 5 days post-fertilization (5dpf), we
observed the expression of miR-126 in the vascular tree. High levels of
miR-126 were detected in large vessels as posterior cardinal vein
(PCV) and dorsal aorta (DA), as well as in intersomitic vessel (ISV),
head vasculature and endocardium (Fig. 1b and S3).
This restricted expression pattern allowed us to examine the level
of miR-126 in zebraﬁsh embryos at different stages of development
by qPCR. The miR-126 was detectable from the 15th somite stage
(around 18 hpf) and further increased in later stages of development,
with a maximal expression level after 5 dpf (Fig. 1C). Moreover, to
determine whether the higher number of vessels in the later stages
could contribute to the enhanced miR126 level, we normalized its
value to the expression level of KDR mRNA, and we still observed an
increase of miR126 during embryo development (Fig. 1D). Notably,
the differentiation of angioblasts from the mesodermal layer occurs
before the 8th somite stage, while the highest expression of miR-126
is concurrent with a mature vascular system [20].
3.2. miR-126 modulates vascular maturation in zebraﬁsh embryos
The speciﬁc spatio-temporal expression of miR-126 suggested that
it could be involved in the process of vascular remodeling. Therefore,
we investigated the role of miR-126 in this process by loss-of-function
experiments in zebraﬁsh embryos injected at the one cell stage with
anti-miR-126 morpholinos.
Gross observation of anti-miR-126 morphant embryos showed
evident abnormalities in the whole body shape likely caused by
pronounced edema (Fig. 2a). The number of living embryos injected
with anti-miR-126 progressively decreased after 4 dpf, with a 10–12 %
of survivors. Nevertheless, experiments with anti-miR-126 performed
on transgenic ﬂk-GFP zebraﬁsh did not display any macroscopic vas-
cular defects, such as a lack of intersomitic vessels or dorsal aorta and
cardinal vein. A more detailed analysis by confocal microscopyFig. 1. miR-126 is speciﬁcally expressed in endothelial cells. (A) Expression levels of
miR-126 were evaluated in human vein EC (HUVEC), murine EC (H-end), human
microvascular EC (HMVEC), smooth muscle cells (SMC) or human dermal ﬁbroblasts
(ﬁbroblast) by qRT-PCR. Data are shown as fold changes (mean±s.e.m.) relative to
breast epithelial cells (MCF-10A), normalized on miR-16 level (*pb0.05; ** pb0.005
compared to SMC). (B) miR-126 expression in whole mount zebraﬁsh embryo at
5 day post fertilization (dpf) detected by speciﬁc anti-miRNA LNA™. Black arrows indi-
cate the main vessels: branchial arches (BA), cardinal vein (CV), dorsal aorta (DA),
heart (H), intersomitic vessels (IS), middle cerebral vein (MCeV), parachordal vessels
(PAV), swim bladder artery (SBA). (C,D) Expression levels of miR-126 were evaluated
on RNA from different stages of zebraﬁsh development. Results are shown as fold
change relative to 1/2 cells stage and normalized on miR-15a level (C) or on VEGFR2
level (D).highlighted maturation defects of the vascular tree (Fig. 2b). In
particular, dorsal aorta and intersomitic vessels appeared to have a re-
duced diameter (Fig. 2c). Besides vascular defects, cardiac development
was also impairedwith a reduction of the size of themyocardium, in par-
ticular of the atrium (Fig. 2d). Although the circulation was functional,0
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Fig. 2.miR-126 modulates vascular maturation in Zebraﬁsh embryos. (A) Lateral view of zebraﬁsh transgenic embryos Tg(ﬂk:GFP)s843 injected with standard control morpholinos
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(backward to the left). Magniﬁcation of the tail vessels is shown in the red boxes. miR126 morphants showed reduced DA diameter (red braces) and improper ISV (white
arrowhead). (C) Quantiﬁcation of the aorta mean diameter. (*, pb0.0005; N=10). (D) Confocal rendered images of Tg(ﬂk:GFP)s843 embryos injected with MO St-Ctl and MO
miR-126. Black arrows indicate the heart.
1929R. Sessa et al. / Biochimica et Biophysica Acta 1823 (2012) 1925–1935with beating heart (data not shown), the heart abnormalities were
found to be the most likely cause of embryo mortality.
3.3. Identiﬁcation of mRNAs regulated by miR-126
To identify genes targeted by miR-126, we developed an assay to
detect the mRNAs differently expressed in cells transfected with
anti-miR-126. EC were co-transfectedwith anti-miR-126 and a plasmid
vector bearing theGFP-coding sequence and three complementary sites
for miR-126 downstream. As a consequence of the presence ofmiR-126binding sites the GFP expression was under the control of miR-126 and
therefore repressed in EC. The transfection of anti-miR-126 allowedGFP
expression by antagonizing the endogenous level of miR-126 (Fig. 3a).
GFP-positive cells were sorted and their expression proﬁle was com-
pared to GFP-negative cells transfected with scrambled anti-miR
(Fig. 3b). The signiﬁcantly upregulated genes were ﬁltered through
bioinformatics analysis to ﬁnd out potential miR-126 targets. A list of
eleven putative targets was work out and one of the most up-
regulated genes was PIK3R2 (p85β) (Table S1). To validate the regula-
tory effect of miR-126 on p85β, qPCR analysis was performed on
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Fig. 3. Identiﬁcation of mRNAs regulated by miR-126. (A) Scheme of the experimental
design carried out to perform the microarray analysis. Plasmid bearing complementary
sites for miR-126 in the 3′UTR of eGFP was co-transfected with miR-126 inhibitor
(anti-miR-126) or its negative control (anti-miR-Scr) in EC, resulting in high and low
ﬂuorescent cells, respectively. (B) Cytoﬂuorimetric analysis of the EC transfected as
indicated above. The two transfected cell populations were sorted according to the
gates shown in the chart in order to isolate EC with normal (black) or reduced level
of miR-126 (red). (C) The p85β mRNA expression level was quantiﬁed on sorted EC
populations by qRT-PCR. Results are shown as fold change relative to untreated EC,
normalized to TBP level. Two independent experiments were performed in triplicate.
*, pb0.05.
1930 R. Sessa et al. / Biochimica et Biophysica Acta 1823 (2012) 1925–1935different RNA samples. Fig. 3c shows that p85βmRNAwasup-regulated
in cells transfected with anti-miR-126 (Fig. 3c).
3.4. p85β is down-regulated by miR-126
To better deﬁne the role of miR-126 on p85β regulation at
post-transcriptional level, Hela cells were co-transfected with pre-
miR-126 together with p85β cDNA containing the 3′UTR sequence or
without this sequence. Pre-miR-126 strongly reduced the expression
of p85β bearing its 3′UTR compared to pre-miR-scramble, but did not
modify the expression of p85β lacking its own 3′UTR (Fig. 4a). These
results were also conﬁrmed in EC transfected with the LNA-anti-
miR-126, which showed a higher amount of p85β protein compared
to EC transfected with control LNA (Fig. 4b). The speciﬁcity ofmiR-126 for the 3′UTR region of p85β was investigated by co-
transfecting Hela cells with pre-miR-126 and plasmid carrying Renilla
coding sequence under the control of p85β 3′UTR. In presence of
miR-126, the activity of the reporter gene was signiﬁcantly reduced
compared to cells transfected with control oligos (Fig. 4c). Moreover,
mutations inserted into the putative 3′UTR target sequence completely
abolished this effect. Similarly, EC co-transfectedwith the reporter gene
and anti-miR-126 showed an increased activation of the reporter gene,
indicating the speciﬁc effect of anti-miR-126 on the 3′UTR sequence of
p85β (Fig. 4d).
3.5. High level of p85β inhibit Ang1-dependent Akt activation
Because p85β is one of the regulatory subunits of the class IA PI3K
enzyme that is activated by tyrosine kinase receptors we extended
previous observation on the regulatory role of miR-126 on VEGF/
VEGFR2 axis to Ang-1/Tie-2 receptor [13,14]. Both signaling pathways
activate the serine/threonine kinase Akt, which is phosphorylated
upon engagement with PIP3 produced by PI3K. Therefore we ana-
lyzed the effect of miR-126 down-regulation on Akt phosphorylation
upon stimulation with VEGF and Ang-1. The anti-miR-mediated
down-regulation of miR-126 increased the expression of p85beta
and slightly reduced the Akt phosphorylation induced by VEGF
(Fig. 5a). Interestingly, the inhibition of Akt was more pronounced
when EC were stimulated with Ang-1 (Fig. 5a). To demonstrate that
the level of p85β was determinant to modulate the Ang1-dependent
Akt activation, we over-expressed the p85β protein by lentiviral infec-
tion in EC with two of MOI. The level of Akt phosphorylation was
completely impaired in p85β over-expressing EC when they were
stimulated both with VEGF and Ang-1 (Fig 5b).
To assess the role of p85β on Ang-1 signaling we silenced p85β in
EC by shRNA, and we evaluated Akt phosphorylation (Fig. S5). There
was no appreciable difference of Akt phosphorylation between
knocked-down and wild-type EC, with the exception of a single
shRNA construct that increases the Akt activation (Fig. S5b). However,
to determine if p85βmight be involved inmiR-126-dependent signaling
defects, we knocked this gene down in EC with reduced levels of
miR-126. The defect in Ang-1-dependent Akt phosphorylation was res-
cued by shRNA-mediated knockdown of p85β (Fig. 5c). Furthermore,
upon Ang-1 stimulation p85β co-immunoprecipitated with Tie-2 and
was tyrosine phosphorylated, suggesting that p85β directly interact
with Tie-2 (Fig 5d).
3.6. Over-expression of p85β inhibits endothelial cells survival and
sprouting induced by Ang1
To determine whether the modulation of Tie-2 signaling by
miR126 and p85β affected the biological response of EC to Ang-1,
the ability to induce capillary-like structures formation in ECM gel
was evaluated. Spheroids of EC embedded in collagen gel were stimu-
lated to sprout with the addition of VEGF, Ang-1 or both in the culture
medium. In absence of angiogenic factors, spheroids of EC did not
sprout in collagen gel(Fig. 6a). Down regulation of miR126 reduced
the EC sprouts length in spheroids stimulated with Ang-1(Fig. 6a).
Similar results were obtained in EC spheroids stimulated with VEGF
(Fig. 6a). Interestingly, a synergic effect was observed in EC stimulated
with both VEGF and Ang-1. In this case a more pronounced inhibitory
effect was appreciated in miR126 knock down EC (Fig. 6a).
The over-expression of p85β in EC reduced the sprouts length of
both VEGF and Ang-1-induced tubular structures compared to EC
transduced with empty vector (Fig. 6b and c).
In addition to its in vitro angiogenic effect, Ang-1 was previously
described to be involved in endothelial apoptosis. The anti-apoptotic
activity was evaluated by the analysis of DNA fragmentation in EC
maintained in serum-deprived medium. Ang-1, as well as VEGF,
exerted its anti-apoptotic effect on EC transduced with control vector.
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1931R. Sessa et al. / Biochimica et Biophysica Acta 1823 (2012) 1925–1935In contrast, the anti-apoptotic effect of Ang-1 was consistently
reduced in p85β over-expressing EC. However, the VEGF treatment
was still able to protect from apoptosis (Fig. 6c). Similar results
were obtained by analyzing apoptosis with nucleosome fragment
detection (Fig. S4). Knocking down p85β did not signiﬁcantly modulate
the anti-apoptotic effect of Ang-1 on EC serum starved for 24 h
(Fig. S5c).
These data demonstrate that high levels of p85β negatively regulate
signaling and biological response to Ang-1 while low levels of p85β do
not affect these activities.
3.7. Ex-vivo angiogenesis is impaired by p85β over-expression
We then studied the role of p85β in the mouse aortic ring angio-
genesis assay (MAR), which recapitulates in vivo angiogenesis.
Although in this assay Ang-1 is not able to activate endothelial
sprouting, it potentiates the effect of VEGF [21]. We over-expressed
p85β by lentiviral infection of aortic rings and we stimulated the
formation of capillary-like structures in type-I collagen gel with VEGF
or VEGF combined with Ang-1.The transduction efﬁciency of p85β on MAR was evaluated by
real-time PCR on cells extracted from the gel. An increase of p85β
mRNA was observed in MAR infected with the lentivirus carrying
the cDNA compared to those infected with GFP alone (Fig. 7a). In
the presence of VEGF, MAR transduced with empty vector sprouted
forming a network of tubular structures, and the addition of Ang-1
to the culture medium signiﬁcantly increased the length of these
structures (Fig. 7b). However, in p85β over-expressing MAR the addi-
tion of Ang-1 did not potentiate the angiogenic effect of VEGF (Fig. 7b)
while the sprouting effect of VEGF alone remained unaffected.
4. Discussion
The relevance of miRNA in the regulation of developmental pro-
cesses and particularly in the deﬁnition of endothelial differentiation
and vascular remodeling is now well demonstrated [22,23]. Speciﬁc
miRNAs required for the correct formation of vascular systems are
being deﬁned and some of them have been functionally characterized
[12,15,24–27]. Among them, miR-126 has been identiﬁed as one of
the most expressed in endothelial cells [13,14]. We found that
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1932 R. Sessa et al. / Biochimica et Biophysica Acta 1823 (2012) 1925–1935miR-126 is speciﬁcally expressed in several cells of endothelial origin
while it is almost completely absent in cells derived from other tis-
sues. Moreover, the high expression level in mammalian EC matches
with the presence of miR-126 in vessels of zebraﬁsh. In zebraﬁsh
embryos, miR-126 only begins to be detectable by sensitive methods,
such as qPCR, after 18 hpf, and reaches maximal expression in adult
animals. This relatively late expression pattern is in agreement with
the phenotype observed in embryo injected with anti-miR-126
morpholinos. Treated embryos normally develop the vascular system,
but at day 5 post-fertilization showed decreased viability, edema and
reduction of vessels diameter, suggesting that miR-126 controls vas-
cular remodelling and maturation [2]. Cardiac defects in the atrium
development have also been observed in anti-miR-126 injected
embryos. The described phenotype is partially coincidentwith previous
observations [13,28], and similar to the phenotype ofmiR-126 knockout
mice [14,29]. Some of these authors suggested that miR-126 enhances
the signaling pathway activated by VEGF stabilizing and maintaining
vessel integrity. However this interpretation is not completely
supported by genetic animal models, in which the expression of VEGF
has been modiﬁed. Actually these studies indicate that VEGF is mainly
implicated in the earliest phase of mammalian vascular development,characterized by angioblast migration and formation of the primitive
plexus. In fact, a single VEGF allele is insufﬁcient to establish a proper
vascular network and mice die early in embryogenesis [1,30].
Moreover, it has been recently demonstrated that miR-126
expression is induced by blood ﬂow, through the zinc ﬁnger transcrip-
tion factor klf2a [31] suggesting that miR-126 is only involved in the
ﬁnal vascular shaping. Therefore, it is not clear why VEGF signaling
should be enhanced by miR-126 at this stage, when the processes of
endothelial differentiation and tube formation are completed. Appar-
ently, vascular maturation requires blocking of excessive angiogenesis
and vessels stabilization by recruitment of mural cells. These activities
are only marginal regulated by VEGF [32] and require other soluble
molecules, including Ang-1 and Ang-2 [33].
Our results show that miR-126 regulates signaling activated by
Ang-1, enhancing the response of EC to this morphogenic factor.
Down-regulation of miR-126 almost completely abolishes endothelial
responses to Ang-1, while signals due to VEGF stimulation, (and
therefore its biological effects) are minimally affected.
Notably, the phenotype shown in zebraﬁsh experiments, in which
miR-126 was down-modulated by speciﬁc morpholino, is similar to
those recently described for Ang-1 morphant [34]. Moreover, vascular
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1933R. Sessa et al. / Biochimica et Biophysica Acta 1823 (2012) 1925–1935leakage, reduced diameter of large vessels and cardiac defects are
common alterations detected both in miR-126 and Ang-1 null mice,
suggesting a genetic interaction of these molecules [2,14].
A possible explanation of the ability of miR-126 to speciﬁcally target
Ang-1/Tie-2 signaling comes from the analysis of its target genes. Many
genes have been postulated to be regulated by miR-126, including
VCAM [35], EGFL7 [36], IRS-2 [37], HOXA9 [38] PAK1 [28] and c-Myb
[39]. However, conclusive results have only been obtained for SPRED1
[13,14,31], while experiments with p85β produced contrasting evi-
dences [13,31,40].
Our screening performed on EC expressing anti-miR-126, allowed
us to focus our attention on PI3KR2, themRNA for the p85β regulatory
subunit of PI3K. In resting cells, the regulatory subunits of PI3K (p85α
and p85β) stabilize the thermally labile catalytic subunits (p110) and
conformationally inhibits its lipid kinase activity. Binding of p85 to
activated receptor tyrosine kinases or adaptor proteins relieves the
basal repression of p110, allowing for the activation of the catalyticsubunit. Although the physiological role of p85β is poorly understood,
it has been demonstrated that a reduction of 20–30% in total p85
regulatory subunits produced by disrupting the p85β gene improves
systemic insulin sensitivity through enhanced signaling downstream
of PI3K in muscle [41,42]. Whether this effect results from the
decrease in p85 monomer, thereby increasing the stoichiometry of
p85/p110/IRS complex [42], or by other mechanisms [43], is not clear.
Interestingly, several evidences indicate that Tie-2 activation by
Ang-1 requires PI3K to carry out any biological effect [44–46] while
it is dispensable for several VEGF functions, such as proliferation,
which are mediated by PLCγ and Ras [47]. We demonstrated that
both p85β mRNA and protein were regulated by miR-126, and that
by altering expression levels of p85β, the signaling initiated by
Ang-1 is severely affected. Indeed, high levels of p85β inhibit both
the Ang-1 anti-apoptotic effect and sprouting formation. Although
we showed that p85β directly interacts with Tie-2, the mechanism
involved in the reduced sensitivity to Ang-1 in p85β over-expressing
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1934 R. Sessa et al. / Biochimica et Biophysica Acta 1823 (2012) 1925–1935cells requires further investigations. It was conceivable that low levels
of p85β increased the biological response to Ang-1 since a similar
effect has been described for the insulin signaling in muscle of
p85β−/− mice [41]. However, by silencing p85β in EC we did not
observe any signiﬁcant enhanced response to Ang-1. This could be
dependent by the modest level of p85β dowregulation or by a tissue
speciﬁc regulatory mechanism. The latter hypothesis is supported by
the lack of increased sensitivity to Insulin in liver of p85β−/− mice
[41] and by the impairment of PI3K activation in cancer cell with
miR126 reduced level of p85β [40].
Moreover, while p85β−/− mice do not exhibit vascular defects,
the same mouse strain with single allele endothelial-cell speciﬁc
deletion of p85α display mild vascular defects in pathological condi-
tions [48]. Notably, thesemice exhibit vascular abnormalities, including
vessels leakage and absence of large vessels, which are similar to those
observed in miR-126 morphant zebraﬁsh [48].
5. Conclusions
In conclusion we suggest that regulation of p85β levels not only
ﬁne-tunes VEGF mediated signals [13] but also has a wider effect on
the regulatory mechanisms of vascularization, as inferred by the
modulation of Ang-1 activities, which are mainly addressed to vessel
stabilization and maturation.
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